Design and methodology of the CAPRICORN trial - A randomised double blind placebo controlled study of the impact of carvedilol on morbidity and mortality in patients with left ventricular dysfunction after myocardial infarction

European Journal of Heart Failure

Volumn 2, Issue 3, 2000, Pages 325-332

  Dargie, Henry J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Beta blocker; Heart failure; Left ventricular dysfunction; Myocardial infarction

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; PLACEBO;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; MEDICAL DECISION MAKING; MEDICAL RESEARCH; METHODOLOGY; MORBIDITY; MORTALITY; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; CARBAZOLES; DOUBLE-BLIND METHOD; GREAT BRITAIN; HUMANS; INCIDENCE; MYOCARDIAL INFARCTION; PRACTICE GUIDELINES; PROPANOLAMINES; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SAFETY; SURVIVAL RATE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0033855091     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(00)00098-2     Document Type: Review

References (40)

1. Short and long term prognosis of acute myocardial infarction since introduction of thrombolysis
2. Sex differences in myocardial infarction and coronary deaths in the Scottish MONICA population of Glasgow 1985 to 1991
3. Effect of time from onset to coming under care on fatality of patients with acute myocardial infarction: Effect of resuscitation and thrombolytic treatment
4. Cumulative meta-analysis of therapeutic trials for myocardial infarction
5. Effects of beta-blockade in sudden cardiac death during acute myocardial infarction and the post-infarction period
6. Effect of verapamil on mortality and major events after acute myocardial infarction (The danish verapamil infarction trial II DAVIT II)
7. Contemporary management of acute myocardial infarction
8. Treatment of myocardial infarction in the United States 1990-1993. Observations from the national registry of myocardial infarction
9. β-Blockade after myocardial infarction: A systematic review and meta regression analysis
10. Tinolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction
11. A randomised trial of propranolol in patients with acute myocardial infarction. I. Mortality results
12. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction
13. GISSI-3 study protocol on the effects of lisinopril, of nitrates, and of their association in patients with acute myocardial infarction
14. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure
15. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction
16. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) study
17. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
18. The cardiac insufficiency bisoprolol study II (CIBIS-II): A randomised trial
19. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF)
20. Major beta-blocker mortality trials in chronic heart failure: A critical review
21. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
22. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: Sub-study of the Studies of Left Ventricular Dysfunction (SOLVD)
23. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction
24. Neuroendocrine activation after acute myocardial infarction
25. Carvedilol
26. The adrenergic pharmacology of carvedilol
27. Carvedilol, a new anti-hypertensive prevents oxidation of human low density lipoprotein by macrophages and copper
28. SB 211475 a metabolite of carvedilol, a novel anti-hypertensive agent, is a potent antioxidant
29. Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection
30. Carvedilol, a new vasodilator and beta adrenoceptoc antagonist, is an antioxidant and free radical scavanger
31. Clinical pharmacology of carvedilol
32. Carvedilol: A novel multiple action antihypertensive drug that provides major organ protection
33. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease
34. Left ventricular remodelling with carvedilol in patients with congestive heart failure due to ischaemic disease
35. Effects of short and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idopathic dilated cardiomyopathy
36. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure
37. Carvedilol improves left ventricular function and symptoms in chronic heart failure: A double-blind randomized study
38. Carvedilol is associated with a reversal of remodeling in chronic heart failure
39. Carvedilol prevents remodeling in patients with left ventricular dysfunction after acute myocardial infarction
40. Carvedilol for heart failure: Clinical trials in progress